Dr. Cusi is the principal investigator of a number of ongoing clinical research projects. His grants focus on cutting-edge research in adult endocrinology, diabetes and metabolism, both on clinical and basic research aspects related to the role of obesity and lipotoxicity in the development of Type 2 diabetes and its complications, in particular, the pathogenesis of NAFLD. He has published more than 90 original articles, invited reviews and book chapters in the main journals in the fields of obesity, diabetes and liver disease. Dr. Cusi is a nationally and internationally recognized investigator and speaker on the impact of NAFLD in humans,. His observation in 2006 (NEJM, 2006) that pioglitazone is an effective pharmacological treatment for NASH in people with prediabetes or T2D, confirmed in a 3-year study (Annals Intern Med, 2016), has been incorporated into all major NAFLD guidelines for the management of NAFLD. His current work centers on discovering underlying mechanisms of NAFLD and new treatments. He is an advocate for liver screening in type 2 diabetes and other groups at high-risk groups of cirrhosis from NASH. Most recently involved in the multidisciplinary 2021 AGA consensus statement, 2021 ALEH NAFLD guidance, 2022 AACE NAFLD clinical practice guideline, and 2023 ADA Standards of Care related to NAFLD.